FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Oncol
Egile Nagusiak: Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark, Zhou, Xin, Zhao, Gexin, Chen, Hong, Li, Xinmin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8216110/
https://ncbi.nlm.nih.gov/pubmed/34164344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.683419
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak